In conclusion, based on a multi-center retrospective study and meta-analysis, we found a negative impact of overweight/obesity on the therapeutic response for HER2 positive breast cancer patients treated with neoadjuvant targeted therapy. Here, ERBB2 is linked to obesity due to melanocortin 4 receptor deficiency.